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Screening studies reveal a much larger number of individuals expected to have alpha-1 anti-
trypsin deficiency than is clinically recognized, with estimates that only about 2e10% of such
individuals have been diagnosed. In the context that recognition of alpha-1 antitrypsin may
prompt specific interventions (e.g., smoking avoidance, testing of family members, genetic
counseling, and consideration of augmentation therapy), diagnosis is important, inviting much
attention for efforts to identify affected individuals.
Strategies to identify affected individuals include both population-based screening and tar-
geted detection, and available studies have employed both approaches, though large-scale po-
pulation-based screening is challenging. As reviewed in this paper, targeted-detection studies
have generally produced a higher rate of detecting disease, and tend to be more successful
with easier sampling techniques. Strategies to enhance detection in targeted studies have
included awareness campaigns, easy testing techniques (such as evaluation of dried blood
spots and home, confidential testing), and inclusive criteria for testing which span the full
spectrum of clinical manifestations of alpha-1 antitrypsin deficiency.
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Alpha-1 antitrypsin deficiency (AATD) is an under-recog-
nized condition with only a minority of affected individuals
detected, long diagnostic delays between initial symptoms
and diagnosis, and evidence that affected individuals may
see many physicians with suggestive symptoms before an
initial diagnosis is made.1e5 In the context that under-
detection of AATD has been appreciated since at least the
early 1990s,1,3,4 and that detecting AATD may prompt
specific interventions (e.g., testing of family members,
emphasis on smoking avoidance, and consideration of
augmentation therapy),6 a variety of efforts have been
undertaken to enhance recognition of individuals with
AATD. The purpose of this paper is to review the issue of
detecting individuals with AATD, both regarding evidence
about the rates at which affected individuals are detected
and the results of interventions undertaken to identify
individuals with AATD.
Rates of detecting individuals with alpha-1
antitrypsin deficiency
Estimates suggest that fewer than 10% of Americans with
severe AATD (defined as having serum levels below the
protective threshold value of 11 mM) are recognized clini-
cally,1,4,7 and that similarly low recognition rates have been
observed in all countries in which the issue has been
addressed.8
Focusing on the United States, extrapolation of data
from population-based screening studies,9,10 evaluations of
patients with COPD,11 and genetic epidemiologic surveys12
lead to convergent estimates of about 60,000e90,000 PI*ZZ
Americans,4 of which only about 6000 have been
identified.7
Several other studies confirm that individuals with
severe AATD escape medical detection. In a study of the
frequency of AATD in St. Louis, Silverman et al. sampled
20,000 blood specimens donated to the St. Louis blood bank
and found 7 who had PI)ZZ deficiency. Extrapolation to
a St. Louis population of 2 million individuals at the time
predicted 700 affected individuals. However, only 28 could
be identified (4%) after contact investigations.10
Reasoning that younger individuals with severe AATD
may be asymptomatic and thus escape medical detection,
Tobin et al. estimated that the majority of PI)ZZ subjects
would present to a pulmonary physician between ages 45
and 54. In a multicenter survey undertaken by the British
Thoracic Association in 1976, they found 90 PI)ZZ individ-
uals in that age band.13 Yet, applying PI)ZZ prevalence
estimates of 0.03% would have predicted 2000 PI)ZZ indi-
viduals in that age range, suggesting that only 4.5% were
identified.13Finally, combining data from the Alpha-1 International
Registry,14 and from the U.S. Alpha-1 Foundation Research
Network Registry,15 which together encompass 21 countries
on 4 continents, indicates approximately 2350 registered
individuals with the PI)ZZ phenotype. Yet, published
genetic epidemiologic surveys estimate about 100,000
PI)ZZ individuals from those countries,16 suggesting that
only 2.4% of individuals have been identified.
Taken together, available estimates from many coun-
tries consistently suggest that only a small minority of
individuals with severe AATD (w2e10%) are recognized
clinically. In the context of such under-recognition,
a variety of efforts have been undertaken to detect such
individuals.
Interventions to detect individuals with
alpha-1 antitrypsin deficiency
Tables 1 and 2 summarize the results of studies undertaken
to detect individuals with AATD. As shown, detection
efforts have included both population-based, true
screening studies, in which unselected groups without
heightened suspicion of having AATD have been broadly
tested (Table 1),9,10,17e20 and case-finding or targeted-
detection efforts (Table 2),11,21e27 in which individuals have
been tested because a heightened suspicion exists of their
having AATD (e.g., either because of clinical manifesta-
tions, such as chronic obstructive pulmonary disease or
cirrhosis, or because of a family history of AATD).
Screening studies
Of the 20 available screening studies listed in Table 1, the
two largest population-based screening studies were con-
ducted by O’Brien et al. in Oregon9 and Sveger in Sweden.28
O’Brien et al. screened 107,038 infants with blood
specimens obtained from a heel stick and collected on filter
paper on the day of discharge. A second sample was
obtained in 75% of these same infants at 4e6 weeks of age.
Abnormal screening results were repeated on all but 26
infants. The study identified 32 children with two or more
abnormal screening tests: 21 with homozygous deficient
phenotypes (ZZ or Z null) and 11 heterozygous for variant
genotypes (including PI)MZ, PI)SZ and others that were not
specified).9
In the largest available population-based screening
study, Sveger screened 200,000 infants representing 95% of
all infants born in Sweden between November 1972 and
September 1974.28,29 Of the 200,000 screenees, the study
identified 127 PI)Z individuals as well as 48 PI)SZ
individuals.
Aggregating the results of the other 18 detection studies
in Table 1 by region shows the following detection rates:
Table 1 Prevalence estimates of specific alpha-1 antitrypsin deficiency phenotypes in selected population screening studies.
Authors Year Location
of study
Subject
population
Number
screened
Prevalence of specific AAT phenotype (%)
ZZ SZ MZ SS MS Other deficiency
phenotypes
Saris et al.19 1972 Finland College students 664 0.15 e 5.12 e e e
Goedde et al.47 1973 Spain Population survey 576 e e 1.04 e 22.7
Vandeville et al.54 1973 Zaire Population survey 132 0 0 0 0 0 LM 5.3, MV 0.76
Webb et al.42 1973 New York Population survey 500 0 0 3.6 0.2 6 FM 2.0, MV 0.2
Cook48 1975 United
Kingdom
Population survey 5588 0.04 0.21 2.02 0.32 7.19
Hoffman and
van den Broek49
1976 Netherlands Population survey 1474 0.07 0.07 2.24 0 2.84 Mnull 1.09
Lieberman et al.43 1976 California High school
students
1841 0 0.27 1.85 0.05 6.90 IM 0.33, MP 0.16,
FM 0.16, Mnull 0.05,
LP 0.05, GM 0.05,
DM 0.05, EM 0.05
Sveger28,29 1976 Sweden Newborns 200,000 0.06 0.02 e e e Znull 0.001,
Snull 0.0005
Evans et al.44 1977 New York Newborns 1010 0 0 1.19 0.89 3.07 MV 0.10
Harada et al.55 1977 Japan Blood donors 856 0 0 0.23 0 0.23 MX 0.12, MN 0.12,
MF 0.36, MV 0.12
Massi and Vecchio53 1977 Somalia Newborns 347 0.86 0.28 0.28 2.59
Morse et al.45 1977 Tucson Population survey 2944 0.07 0.20 3.0 7.1 MF 0.07, IM 0.03
Klasen et al.50 1978 Italy Hospital
outpatients
202 0 0 1.98 0 4.95 MF 1.49, MI 0.49
O’Brien et al.9 1978 Oregon Newborns 107,038 0.02 0.01 e e
Dijkman et al.17 1980 Netherlands Newborns 95,083 0.03 e e 0.04 e Non-M 0.01
Dykes et al.46 1984 Minnesota Blood donors 904 0 e 2.77 0.22 4.09 MI 0.55, MF 0.44,
MP 0.22, SF 0.11
Kimpen et al.18 1988 Belgium Newborns 10,329 0.06 0.12 0.97 0.01 0.88
Silverman et al.10 1989 St. Louis Blood donors 20,000 0.04 0.01 0.01
Spence et al.20 1993 New York
State
Newborns 11,081 0.03 0.05 0.53 0.01 0.09
Kaczor et al.51,52 2007 Poland Random sample 859 0 0 2.10 0.12 3.26
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114,775 (0.03%), Africa 3/479 (0.63%) and Asia 0/856.
As a corollary of these large population-based screening
studies, important insights regarding the natural history of
AATD have emerged from follow-up of the individuals
identified as having PI)ZZ AATD at birth. Specifically, in
both the 15-year follow-up of individuals screened in Ore-
gon,30 and in the 30-year follow-up of individuals screened
in Sweden,31 individuals tested had normal lung function at
mean ages of 15.1 and 30.6 years, respectively. Further-
more, the rate of cigarette smoking among AATD individuals
was lower than that among age-matched peers,30 or the
population as a whole.31
Targeted-detection studies
Various studies have undertaken targeted detection of
individuals with alpha-1 antitrypsin deficiency using
a variety of testing methods and target populations. For
example, some studies have examined the prevalence of
severe AATD among patients seen at single health care
facilities,11,26 while others have conducted regional or
national awareness campaigns with associated free
testing.21,24,25,27 Still other studies have attempted toenhance detection of individuals with severe AATD by
suggesting alpha-1 antitrypsin testing to clinicians
receiving the results of pulmonary function tests showing
airflow obstruction or by directly approaching patients
whose pulmonary function tests are consistent with
chronic obstructive pulmonary disease (COPD). The results
of these various studies are listed in Table 2 and discussed
below.
In an early study at the Sepulveda Veterans Adminis-
tration Hospital, Lieberman et al. performed alpha-1 anti-
trypsin blood tests on 965 consecutive Veterans attending
the COPD Clinic using a trypsin inhibitory capacity assay,11
and found that PI)ZZ individuals comprised 1.9% of those
tested.
In a second early study, Matzen et al. used crossed
electrophoresis and serum trypsin inhibitory capacity
assays to determine the phenotypes of 225 patients previ-
ously diagnosed as having abnormal pulmonary function
tests. While no PI)ZZ individuals were found, 2.7% (NZ 6)
were PI)MZ, 7.1% (NZ 16) were PI)MS, and 0.4% (NZ 1)
were PI)FF.26
To our knowledge, 5 studies have coupled awareness
campaigns with free testing for alpha-1 antitrypsin defi-
ciency, either regionally or nationally (Table 2).21,22,24,25,27
Table 2 Results of studies undertaken to detect individuals with AATD.
Authors Detection strategy Number of
patients
Prevalence of specific AAT phenotype (%)
PI*ZZ PI*SZ PI*MZ PI*SS PI*MS Other
Matzen et al.26 Case-finding (individuals
with abnormal PFTs)
225 (US) 0 2.7 7.1 PIFF 0.4
Lieberman et al.11 Case-finding (patients with
advanced COPD admitted for
carotid body surgery)
965 (US) 1.9 0.3 7.7 0.3 10.1
Luisetti et al.,25
Ferrarotti et al.33
Case-finding (missing or reduced
a1 globulin band, early-onset
emphysema, familial cluster,
first-degree relative of subjects
with ascertained AATD or MZ
heterozygosity)
2127 (Italy) 7.3 1.9 17.9 0.05 6.6 Null Null 0.4,
Z null 0.2,
Rare variants 0.2
Wencker et al.27 Targeted detection (patients
with COPD, emphysema, asthma,
or bronchiectasis)
1060 (Germany) 0 0.2 3.7 0.09 3.4 PI*M Null 0.09
Brantly et al.22 Case-finding (targeted detection
in COPD with education program
and free testing)
969 (Florida) 3.2 0.4 11
de la Roza
et al.24
Case-finding (patients with COPD) 2137 (Spain) 0.37 0.14 0.14
Corda et al.23 Case-finding (emphysema without
risk factors or of early-onset,
spontaneous pneumothorax,
cervical artery dissection,
PAS positive bodies in liver,
isolated transaminase elevation,
ANCA positive, or low alpha-1
proteins on protein
electrophoresis)
285 (Italy) 12 8 62 14 PI*ZI 0.35,
PI*ZMmalton 0.35,
PI*MMmalton 2.1
Bals et al.21 Case-finding linked
to an AATD awareness program
2696 (Germany) 9.9 2.0 18.1 3.6 Rare
phenotype 0.5
Rahaghi et al.34 Case-finding 29 (US) 0 1
PAS, periodic acid-Schiff; ANCA, antineutrophil cytoplasmic antibodies.
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coupled with free testing for AATD (using a polymerase
chain reaction blood spot test), Bals et al. sent mailings to
all general practitioners and both pediatric and pulmonary
specialists in Germany, established a web site, and
announced the study at various national meetings. Of
17,688 test kits requested, 2722 were returned and 2696
were technically testable. Among these 2696, the overall
prevalence of severe deficient phenotypes was 12.4%
(including PI)ZZ e 9.9% and PI)SZ e 2.0%, Table 2).21
Campbell reported the results of an alpha-1 antitrypsin
detection service which makes available free testing for
AATD (immunoassay, isoelectric focusing, and polymerase
chain reaction analysis for specific alleles) on clinicians’
submitting dried blood spot specimens. Between March
1991 and February 29, 2000, 30,631 samples had been
submitted, of which 1021 (3.3%) were said to have been
‘‘diagnosed with the disease’’ (though the specific pheno-
type was not specified in the available report.)32
de la Roza and colleagues reported their experience
with a 2-phase case-finding program in Spain using both
immunonephelometry and polymerase chain reaction
testing of dried blood spot specimens for the Z and Salleles. In phase 1 of the program, of 971 samples collected
from 7 pulmonologists who were encouraged to submit
samples from their patients with COPD, 5 (0.5%) were found
to be PI)ZZ. In phase 2 in which members of the COPD task
force of the Spanish Society of Pneumology and Thoracic
Surgery were encouraged to submit samples, 1166 samples
were collected, of which PI)ZZ, PI)SS, and PI)SZ pheno-
types were observed in 3 samples (0.3%) each. With both
phases taken together, of 2137 samples collected, the
PI)ZZ phenotype was found in 0.37% (NZ 8).24
In a preliminary communication of a targeted-detection
program in Florida reported by Brantly et al., of 969
samples analyzed, PI)ZZ specimens were found in 31
(3.2%), PI)SZ in 4 (0.4%), and PI)MZ in 107 (11%).22
Corda et al. reported the results of a targeted-detection
program in an Italian hospital in which nephelometry and
polymerase chain reaction assays were performed when
patients presented with the following suggestive diagnoses:
emphysema at onset 45 years or without recognized risk
factors, spontaneous pneumothorax, cervical artery
dissection, liver biopsies showing periodic acid-Schiff posi-
tive inclusions, unexplained and isolated elevated trans-
aminases, antineutrophil cytoplasm antibodies, or low
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of 285 specimens collected over 9 years, 211 (74%) alpha-1
antitrypsin deficient specimens were identified as follows:
PI)ZZ e 12% (NZ 26), PI)SZ e 8% (NZ 17), PI)ZI e 0.35%
(NZ 1), PI)ZMmalton e 0.35% (NZ 1), PI)MZ e 62%
(NZ 131), PI)MS e 14% (NZ 29), and PI)MMmalton e 2.1%
(NZ 6).23
Wencker et al. conducted a targeted-detection study for
AATD in 7 German physicians’ offices e 3 pulmonologists
and 4 general practitioners. Between March and June 1999,
patients with COPD, asthma, or bronchiectasis were
offered AATD testing using dried blood spot samples for
immunoassay and isoelectric focusing. Of 1060 evaluable
samples, 77% were submitted by pulmonologists. None of
the 1060 samples was PI)ZZ, 3 (0.2%) were PI)SZ, 1 (0.09%)
was PI)M Null, 1 (0.09%) was PI)SS, 39 (3.7%) were PI)MZ
and 36 (3.4%) were PI)MS.27
Luisetti et al. reported the results of an Italian program
in which dried blood spot alpha-1 antitrypsin tests were
distributed to hospitals and clinics between 1993 and 1998.
Testing was suggested for individuals with low alpha-1
antitrypsin protein amounts on serum protein electropho-
resis specimens, individuals known to have serum alpha-1
antitrypsin levels <80 mg/dl, those with early-onset
emphysema, a history of familial COPD, or first-degree
relatives of those known to have AATD, including PI)MZ. Of
1841 samples, a total of 151 (18%) were found to have
AATD. With both phases taken together, the number of
deficient individuals found was as follows: PI)ZZ 6.4%
(NZ 118), PI)SZ 0.9% (NZ 17), PI)Null Null 0.4% (NZ 8),
PI)Z Null 0.2% (NZ 4), and rare alleles (not specified in the
report) 0.2% (NZ 4).25 An update of this study through
2006, which extended the sample to 2127, showed similar
results (Table 2).33
Of the targeted-alpha-1 antitrypsin deficiency detection
programs shown in Table 2, the highest detection rates are
found in those that include an awareness campaign,21,22 or
in those that broadly target specific clinical features of
alpha-1 antitrypsin deficiency.23,25,33 On the other hand,
several studies which tested a relatively small number of
individuals (e.g., <200) identified no AATD individuals.26,34
In an analysis of the ‘‘number needed to test’’ in order to
identify a single individual with severe deficiency of alpha-1
antitrypsin, Rahaghi et al. estimated that approximately
150 targeted patients would need to be tested in order to
have a 95% confidence of detecting a single individual with
severe AATD in a population in which the prevalence of
severe AATD among COPD patients is 2%.34
As another strategy to enhance clinicians’ awareness of
and testing for AATD, Rahaghi et al. appended physician
alerts suggesting testing for AATD to the pulmonary func-
tion test reports of patients found to have fixed airflow
obstruction. During the ‘‘physician alert intervention
period,’’ the rate of testing for AATD was higher than during
the control period (prior to issuing the physician alerts, 13%
vs. 6%), though the absolute rate of testing remained low
and no patient with severe AATD was detected during the
study.34
Enthusiasm to encourage clinicians to test all symp-
tomatic adults with fixed airflow obstruction has prompted
a study that is currently being launched in which an elec-
tronic medical record prompt will go the clinician who hasordered a pulmonary function test whenever the patient’s
pulmonary function test result indicates fixed airflow
obstruction. Finally, the Alpha-1 Foundation has launched
a study, also currently underway, in which patients whose
pulmonary function tests show fixed airflow obstruction are
approached immediately in the pulmonary function labo-
ratory and offered the opportunity to be tested for AATD.
Whether these strategies of electronic prompts or directly
approaching patients for AATD testing will enhance detec-
tion must await the results of these planned or recently
initiated studies.
Other strategies to encourage testing for AATD include
developing tests that are easy and that are acceptable to
patients. Such tests are available and include alpha-1
antitrypsin genotyping from mouthwash specimens,35
testing of dried blood spots,27 and home testing with
confidential results reporting (the Alpha-1 Coded Testing
[ACT] Trial).36
In considering the potential limitations of targeted-
detection programs, one shortcoming is that targeting
symptomatic individuals overlooks the possibility of
detecting asymptomatic and/or clinically unaffected indi-
viduals with severe deficiency of alpha-1 antitrypsin. The
magnitude of such a bias has been suggested by studies
which estimate the frequency with which individuals with
severe AATD actually develop clinical signs or symptoms.
For example, Tobin et al. attempted to lessen the selection
bias of studying individuals attending a chest clinic by
assessing the risk of developing emphysema in PI)ZZ
siblings of index cases.13 In this study, emphysema was
radiographically confirmed in 90% of PI)ZZ smokers
compared to 65% of PI)ZZ non-smokers.13 Similarly, data
from the Swedish National Registry, in which only 29% of the
participants were identified on the basis of lung disease,
showed that in adult PI)ZZ homozygotes, 29% of never-
smokers and 10% of ever-smokers were healthy.37 Post-
mortem series from Sweden,37 and computed tomographic
studies,38 also indicated that approximately 14e20% of
PI)Z homozygotes escaped developing emphysema. de la
Roza et al. have estimated that 35e60% of PI)ZZ develop
COPD.24 Finally, Silverman et al. reported that only 10 of 30
PI)ZZ individuals, who were not diagnosed because of
existing lung disease, had FEV1< 65%.
39 Taken together,
the results of these studies support the notion that targeted
detection, which has been shown to be cost-effective by
the conventional criterion of <$50,000 per quality-adjusted
life-year,40 may underestimate the prevalence of individ-
uals with AATD by virtue of overlooking those who are free
of clinical manifestations of AATD. Population-based
studies avoid this potential source of bias but are, of
course, challenging to perform on a large scale.Summary
Alpha-1 antitrypsin deficiency remains under-recognized
despite increased attention to the issue through the
publication of management guidelines,1 awareness
campaigns by various patient advocacy organizations, and
a growing number of recent publications.41 A diagnosis of
AATD may have important implications, including testing of
family members, genetic counseling, smoking avoidance,
340 L.S. Aboussouan, J.K. Stolleravoidance of high-risk occupations, and consideration of
augmentation therapy. Enthusiasm to enhance detection
has prompted a variety of studies to identify affected
individuals, including direct population screening, targeted
detection of individuals regionally or nationally, and strat-
egies to enhance clinician’s suspicion and testing for alpha-
1 antitrypsin deficiency. Compared to population-based
studies, which are difficult to perform on a large scale,
targeted-detection programs have a much higher rate of
detection of AATD, are easier to perform, and are more
cost-effective, though they may miss asymptomatic indi-
viduals. Characteristics of the studies that have the highest
detection rates include those that provide confidential and
easy to perform testing, and broadly target specific clinical
features of alpha-1 antitrypsin deficiency combined with an
awareness campaign.21,22Conflict of interest
Dr. Aboussouan has no conflicts of interest to disclose.
Dr. Stoller has indicated that he has been a consultant for
Talecris and Baxter corporations.
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